An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors

Condition:   Neuroendocrine Tumors Intervention:   Drug: Surufatinib Combined With Temozolomide and S-1 Sponsor:   Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials